Literature DB >> 20980826

Shifting senescence into quiescence by turning up p53.

Manuel Serrano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20980826      PMCID： PMC3578181          DOI： 10.4161/cc.9.21.13785

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  13 in total

1.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

2.  Weak p53 permits senescence during cell cycle arrest.

Authors:  Olga V Leontieva; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2010-11-10       Impact factor: 4.534

3.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 4.  Senescence in tumours: evidence from mice and humans.

Authors:  Manuel Collado; Manuel Serrano
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.

Authors:  Zhaohui Feng; Wenwei Hu; Elisa de Stanchina; Angelika K Teresky; Shengkan Jin; Scott Lowe; Arnold J Levine
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

7.  A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

Authors:  Andrea Alimonti; Caterina Nardella; Zhenbang Chen; John G Clohessy; Arkaitz Carracedo; Lloyd C Trotman; Ke Cheng; Shohreh Varmeh; Sara C Kozma; George Thomas; Erika Rosivatz; Rudiger Woscholski; Francesco Cognetti; Howard I Scher; Pier Paolo Pandolfi
Journal:  J Clin Invest       Date:  2010-02-08       Impact factor: 14.808

8.  Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.

Authors:  Andrei V Budanov; Anna A Sablina; Elena Feinstein; Eugene V Koonin; Peter M Chumakov
Journal:  Science       Date:  2004-04-23       Impact factor: 47.728

9.  Growth stimulation leads to cellular senescence when the cell cycle is blocked.

Authors:  Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2008-11-12       Impact factor: 4.534

10.  p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Authors:  Andrei V Budanov; Michael Karin
Journal:  Cell       Date:  2008-08-08       Impact factor: 41.582
View more
  25 in total

1.  Rapamycin induces pluripotent genes associated with avoidance of replicative senescence.

Authors:  Tatiana V Pospelova; Tatiana V Bykova; Svetlana G Zubova; Natalia V Katolikova; Natalia M Yartzeva; Valery A Pospelov
Journal:  Cell Cycle       Date:  2013-12-02       Impact factor: 4.534

Review 2.  Rapalogs in cancer prevention: anti-aging or anticancer?

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2012-11-14       Impact factor: 4.742

Review 3.  The cell fate: senescence or quiescence.

Authors:  Menderes Yusuf Terzi; Muzeyyen Izmirli; Bulent Gogebakan
Journal:  Mol Biol Rep       Date:  2016-08-24       Impact factor: 2.316

4.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

5.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06

Review 6.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 7.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

8.  Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 9.  Answering the ultimate question "what is the proximal cause of aging?".

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 10.  Advances in targeting signal transduction pathways.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Lin Sun; Nicole M Davis; Stephen L Abrams; Richard A Franklin; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli; Massimo Libra; Saverio Candido; Giovanni Ligresti; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Marco Donia; Ferdinando Nicoletti; Jerry Polesel; Renato Talamini; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Michele; Agostino Tafuri; Joanna Dulińska-Litewka; Piotr Laidler; Antonio B D'Assoro; Lyudmyla Drobot; Drobot Umezawa; Giuseppe Montalto; Melchiorre Cervello; Zoya N Demidenko
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.